50岁及以上阿尔伯塔省居民带状疱疹疫苗有效性:回顾性队列研究
该回顾性队列研究纳入阿尔伯塔省2009年6月30日登记且年满50岁的1,094,236人,其中85,439人(7.80%)接种带状疱疹疫苗,随访至2015年11月1日。接种后第一年调整疫苗有效性为50.02%(95%CI:44.71%,54.83%),至第五年降至14.00%(95%CI:-20.99%,38.88%),无显著效果。
要点
- 队列共1,094,236人,85,439人(7.80%)接种带状疱疹疫苗。
- 接种后第一年调整疫苗有效性为50.02%(95%CI:44.71%,54.83%)。
- 至第五年疫苗有效性降至14.00%(95%CI:-20.99%,38.88%),无显著效果。
核心结论
- 研究结果与其他基于人群的研究观察一致,为决策者审查带状疱疹疫苗公共资助决策提供人群水平数据。
研究设计与样本
- 回顾性队列研究,使用阿尔伯塔省行政健康数据,队列为2009年6月30日登记且年满50岁的阿尔伯塔省居民,共1,094,236人,其中85,439人(7.80%)接种带状疱疹疫苗,随访至2015年11月1日(6年)或直至发生带状疱疹、死亡或取消保险。
主要发现
- 带状疱疹发病率为9.03例/1000人年(95%CI:8.95,9.11),共49,243例。
- 接种后第一年调整疫苗有效性为50.02%(95%CI:44.71%,54.83%)。
- 至第五年疫苗有效性降至14.00%(95%CI:-20.99%,38.88%),无显著效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the effectiveness of shingles vaccine in preventing incident shingles among Alberta residents aged 50 years or older over the period 2009 - 2015, using administrative health data. METHODS: The cohort comprised of Albertans from the Alberta Health Care Insurance Plan Registry (AHCIP) as of June 30, 2009 and aged 50 years or older. Those who received shingles vaccine were identified from the provincial pharmaceutical information network. The occurrence of incident shingles was identified through both inpatient and outpatients/community care data. Incident shingles was defined as the earliest dated record of ICD 9-CM 053 or ICD-10-CA B02. Starting on November 1, 2009, individuals with no history of shingles or shingles vaccination were followed until Nov 1, 2015 (6 years), or until shingles incidence, death, or AHCIP cancellation (including leaving Alberta). Vaccine effectiveness (VE) was estimated as the inverse of the relative risk of developing incident shingles in each year following vaccination compared to time at risk without vaccination, while adjusting for age, sex, income quintile, and immune compromising conditions (identified from physician claims, inpatient, and cancer registry data). RESULTS: There were 1,094,236 individuals in the cohort, with 85,439 (7.80%) vaccinated individuals. The shingles incidence rate was 9.03 [95% CI: 8.95, 9.11] cases per 1,000 person years (49,243 cases). Adjusted VE in the first year following immunization was 50.02% [95% CI: 44.71%, 54.83%] against incident shingles, decreasing to no effect by the fifth year (VE = 14.00% [95% CI: -20.99%, 38.88%]). CONCLUSIONS: Our findings are consistent with observations from other population based studies and provide population level data for policy-makers to review when making decisions related to public funding of shingles vaccine.
引用
- McDonald BM, Dover DC, Simmonds KA, et al. The effectiveness of shingles vaccine among Albertans aged 50 years or older: A retrospective cohort study. Vaccine. 2017. PMID: 29128385. doi:10.1016/j.vaccine.2017.10.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。